

Mr Shri Jaḡat Prakash Nadda
Union Minister
Ministry of Health & Family Welfare
155 - A, Nirman Bhawan
New Delhi - 110108
India

25 July 2017

Dear Minister,

Re: Approval of Rotavirus Vaccine Support for India

We are writing in relation to India's application to Gavi, the Vaccine Alliance, for its Phase 3 Rotavirus Vaccine support, which was submitted to the Gavi Secretariat in December 2016.

In line with the provisions stated in the Annex 6 of the Partnership Framework Agreement (PFA), the application was reviewed in country by an independent review team, who made recommendations to the country regarding the proposal. Following receipt of responses to these recommendations, we are pleased to inform you that **Gavi has approved India's application for Phase 3 of Rotavirus Vaccine support.**

Given the ongoing tender, Gavi cannot commit to vaccine doses beyond the first year of support. For country planning purposes in advance of the scheduled vaccine introduction, Gavi approved the first year of support, based on the public Bharat Rotavac price.

Based on the starting date of the Phase 3 vaccine introduction in September 2017 as indicated in the application, the following Decision Letter approves the number of doses for the period September - December 2017 (Year 1 of support).


After the completion of the tender process, Gavi will communicate the number of doses for 2018, Year 2 of support.

We reiterate that the provisions of the PFA / Annex 6 shall apply to all Gavi programme funding and Decision Letters form an integral part of the PFA. Any capitalised terms used in this letter have the meaning given to them in the PFA. The Gavi Board's decision to provide support for India's HSS programme is also subject to the provisions of Annex 6 of the PFA, in particular the commitment of the Government of India to provide additional costs required as well as sustain the programme after the transition out of Gavi support, and to implement the programme as set out in the approved Performance Framework.

I would like to thank you for your continued commitment to strengthen the immunisation programme in India and encourage you to not hesitate to contact the Senior Country Manager for India, Carol Szeto (cszeto@gavi.org), if you have any questions or concerns.

We remain at your disposal for any further enquiry.

Yours sincerely,



Hind Khatib-Othman
Managing Director, Country Programmes

Cc:
PS, The Minister of Health and Family Welfare
PS, The Minister of Finance
Secretary, Ministry of Health and Family Welfare
Additional Secretary, MD NHM, Ministry of Health and Family Welfare
Joint Secretary, Ministry of Health and Family Welfare
Deputy Commissioner (Immunization); MoHFW
Deputy Commissioner (UIP), MoHFW
WHO Country Representative
UNICEF Country Representative
WHO HQ
UNICEF Programme Division
UNICEF Supply Division

India Support for Rotavirus Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: India		
2. Grant number: 17-IND-13a-X		
3. Date of Decision Letter: 25 July 2017		
4. Date of the Partnership Framework Agreement: 12 June 2015		
5. Programme title: New Vaccine Support (NVS), Rotavirus Routine		
6. Vaccine type: Rotavirus		
7. Requested product presentation and formulation of vaccine: Rotavirus, 10 vial presentation, 3 doses schedule		
8. Programme duration¹: 2017		
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)		
	2017	Total ²
Programme Budget (US\$)	US\$6,961,500	US\$6,961,500
10. Vaccine introduction grant (in US\$): Not applicable		
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ³		
Type of supplies to be purchased with Gavi funds in each year		2017
Number of Rotavirus vaccines doses		7,037,600
Annual Amounts (US\$)		US\$6,961,500
12. Procurement agency: UNICEF		
13. Self-procurement: Not applicable		
14. Co-financing obligations: Not applicable		
15. Operational support for campaigns: Not applicable		

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the amount that Gavi has approved.

16. Additional reporting requirements:

Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future annual amounts: Not applicable

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May 2018
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat

17. Financial clarifications: Not applicable

18. Other conditions: Not applicable

Signed by,



On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

25 July 2017